樂觀
$28.00
情境價格
$24.700
+0.193 (+0.78%)收盤時
Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others.
Baxter International Inc is a good buy right now due to its current price of $25.28, which is below the average analyst price target of $27.67, indicating potential upside. Additionally, the stock has shown a strong year-to-date change of +29.64% and a recent 5-day change of +3.82%, suggesting positive momentum. However, the main risk is the negative net income reported in Q4 2024 at -$512 million, which reflects ongoing profitability challenges that investors should monitor closely.
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Baxter to Host Q3 2026 Financial Results Conference Call

Baxter Releases 2026 Connected Hospital Report

Baxter International Raises 2026 Sales Outlook

Baxter Appoints New CFO and Reaffirms Full-Year Outlook

Baxter International Inc. Announces Cash Tender Offer Pricing
Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Baxter International Inc is a good buy right now due to its current price of $25.28, which is below the average analyst price target of $27.67, indicating potential upside. Additionally, the stock has shown a strong year-to-date change of +29.64% and a recent 5-day change of +3.82%, suggesting positive momentum. However, the main risk is the negative net income reported in Q4 2024 at -$512 million, which reflects ongoing profitability challenges that investors should monitor closely.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。